Turning Cell Signaling against Cancer
Researchers Use Single-Molecule Assays, Splice-Switching Oligonucleotides, and Fusion Constructs
Virus Supply Vexes Gene Therapy Developers, CMOs
Some Contract Manufacturing Organizations Are Ramping Up Capacity in Preparation for a Boom in Viral Vector Demand
Genome-Wide Analysis of the Transcription Start Sites and Promoter Motifs of Phytoplasmas
RNA-Seq of Phytoplasmas Reveals Clues about Transcription Start Sites and Consensus Promoter Sequences
Novel Viral Vectors for Gene Therapy
Synthetic Viral Vectors Show Promise for Mitigating Immune Response to Gene Therapy
For full access to this article login to GEN Select now.
Driving Successful Assay Development
Host of Therapeutic Classes Require Continuous Updating of Technology
- Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the complexities inherent in developing biologics, there are a growing number of licensed biological products on the market. IBC’s “Bioassay and Development” meeting held earlier ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.